Steroidal glycolipids as host resistance stimulators against viral infection
US5019568A · kind A · utility
1Cited by
7References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 1989 |
| Grant date | May 28, 1991 |
| Priority date | — |
| Expiry date | Jun 21, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are pharmaceutical compositions for enhancing human host resistance against opportunistic infection in an individual immunocompromised by an AIDS-related virus, consisting essentially of an anti-viral, anti-AIDS drug selected from the group consisting of ansamycin, ribavirin, dideoxycitidine, HPA-23, AL-721, foscarnet, and azidothymidine and a glycolipid compound consisting essentially of the formula: ##STR1## where: R.sup.1 is .alpha. or .beta.-D-1-thiomannopyranoside, .alpha. or .beta.-L-1-thiofucopyranoside.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.